Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536
| العنوان: | Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536 |
|---|---|
| المؤلفون: | John V. Heymach, Philip C. Mack, Karen Kelly, Mario R. Velasco, Fred R. Hirsch, Mary W. Redman, Edward S. Kim, Roy S. Herbst, James J. Moon, Shaker R. Dakhil, David R. Gandara |
| المصدر: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 8, iss 12 Kim, ES; Moon, J; Herbst, RS; Redman, MW; Dakhil, SR; Velasco, MR; et al.(2013). Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer SWOG S0536. Journal of Thoracic Oncology, 8(12), 1519-1528. doi: 10.1097/JTO.0000000000000009. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/5v47h38xTest |
| بيانات النشر: | eScholarship, University of California, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Oncology, Male, Lung Neoplasms, Cetuximab, Cardiorespiratory Medicine and Haematology, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, Clinical endpoint, Non-Small-Cell Lung, Humanized, 0303 health sciences, Middle Aged, Prognosis, 3. Good health, Survival Rate, Bevacizumab, Tolerability, 030220 oncology & carcinogenesis, Female, medicine.drug, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Paclitaxel, Clinical Sciences, Oncology and Carcinogenesis, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Article, Antibodies, 03 medical and health sciences, Internal medicine, medicine, Humans, Frontline, Oncology & Carcinogenesis, Lung cancer, Survival rate, 030304 developmental biology, Neoplasm Staging, Aged, business.industry, Non–small-cell lung cancer, Carcinoma, medicine.disease, Regimen, chemistry, Feasibility Studies, business, Non-small-cell lung cancer, Follow-Up Studies |
| الوصف: | Introduction: Cetuximab and bevacizumab have each been demonstrated to prolong survival when added to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). However, the potential benefit of combining cetuximab and bevacizumab together with a platinum-based doublet had not been explored. We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. Methods: Patients received with up to six cycles of carboplatin (area under curve 6), paclitaxel (200 mg/m2), cetuximab (400 mg/m2day 1 then 250 mg/m2weekly), and bevacizumab (15 mg/kg) every 21 days. Patients with an objective response or stable disease received maintenance cetuximab (250 mg/m2weekly) and bevacizumab (15 mg/kg every 21 days) until disease progression. The primary endpoint was safety as defined by the frequency and severity of hemorrhagic toxicities. Secondary endpoints included response rate, progression-free survival, overall survival, and toxicity. Molecular biomarkers were assessed in an exploratory manner. Results: The primary endpoint of grade 4 or higher hemorrhage of 2% (95% confidence interval: 0%-7%) met prespecified criteria for safety. One hundred ten patients were enrolled. There were four treatment-related deaths including lung hemorrhage (2), infection (1), and unknown (1). Median progression-free survival was 7 months and median overall survival was 15 months. The response rate was 56% with an overall disease control rate of 77%. Conclusion: This regimen was safe, feasible, and effective as a frontline treatment of advanced NSCLC, providing the basis for the ongoing phase III trial S0819. Copyright © 2013 by the International Association for the Study of Lung Cancer. |
| وصف الملف: | application/pdf |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a22cb9fee1674df9b93161b24076efabTest https://escholarship.org/uc/item/5v47h38xTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a22cb9fee1674df9b93161b24076efab |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |